Data / Drug companies / Aminosalicylate
Aminosalicylate drugs: 4 drugs from 51 companies in the FDA NDC directory
Aminosalicylate is an FDA established pharmacologic class. The FDA National Drug Code Directory lists 84 products in this class from 51 companies, covering 4 drugs by generic name. The main marketing category is generic drugs (ANDA), and the newest product started marketing on September 1, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- 51Companies
- 84Products
- 4Drugs by generic name
Drugs in the Aminosalicylate class
Ranked by number of companies that list the drug.
| Drug | Products here | Companies listing it |
|---|---|---|
| Mesalamine | 60 | 41 |
| Sulfasalazine | 14 | 10 |
| Balsalazide disodium | 9 | 9 |
| Olsalazine sodium | 1 | 1 |
Companies with the most products in this class
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Zydus Lifesciences Limited | 5 | tablet, delayed release; capsule | Generic drugs (ANDA) | August 25, 2023 |
| American Health Packaging | 4 | tablet, delayed release; capsule, extended release | Generic drugs (ANDA) | September 6, 2022 |
| Bryant Ranch Prepack | 4 | tablet, delayed release; capsule | Generic drugs (ANDA) | June 3, 2023 |
| Takeda Pharmaceuticals America, Inc. | 4 | tablet, delayed release; capsule | New drug applications (NDA) | August 29, 2017 |
| Camber Pharmaceuticals, Inc. | 3 | capsule, extended release; tablet, delayed release | Generic drugs (ANDA) | August 13, 2025 |
| Golden State Medical Supply, Inc. | 3 | tablet, delayed release; capsule, extended release | Generic drugs (ANDA) | June 6, 2023 |
| Teva Pharmaceuticals USA, Inc. | 3 | tablet; capsule, extended release | Generic drugs (ANDA) | December 15, 2022 |
| Zydus Pharmaceuticals USA Inc. | 3 | tablet, delayed release; capsule, extended release | Generic drugs (ANDA) | August 13, 2021 |
| A-S Medication Solutions | 2 | tablet | Authorized generics (NDA) | July 1, 2003 |
| AvPAK | 2 | capsule; capsule, extended release | Generic drugs (ANDA) | January 16, 2023 |
| Bryant Ranch Prepack | 2 | tablet; suppository | Generic drugs (ANDA) | December 15, 2022 |
| Chartwell RX, LLC | 2 | tablet, delayed release; tablet | Generic drugs (ANDA) | June 3, 2023 |
| Mylan Pharmaceuticals Inc. | 2 | tablet, delayed release; tablet | Authorized generics (NDA) | May 5, 2005 |
| Pfizer Laboratories Div Pfizer Inc | 2 | tablet, delayed release; tablet | New drug applications (NDA) | June 20, 1950 |
| Rising Pharma Holdings, Inc. | 2 | tablet; suppository | Generic drugs (ANDA) | November 4, 2025 |
| Sandoz Inc | 2 | capsule, extended release | Generic drugs (ANDA) | July 21, 2026 |
| Sun Pharmaceutical Industries, Inc. | 2 | capsule, extended release; tablet, delayed release | Generic drugs (ANDA) | May 13, 2022 |
| Sunrise Pharmaceutical, Inc. | 2 | tablet, delayed release; tablet | Generic drugs (ANDA) | December 11, 2025 |
| Viatris Specialty LLC | 2 | capsule, gelatin coated; suspension | New drug applications (NDA) | March 24, 2016 |
| Zydus Pharmaceuticals USA Inc. | 2 | suppository; capsule | Generic drugs (ANDA) | August 25, 2023 |
| Actavis Pharma, Inc. | 1 | suppository | Generic drugs (ANDA) | April 23, 2021 |
| Actavis Pharma, Inc. | 1 | tablet, delayed release | Generic drugs (ANDA) | March 26, 2018 |
| Alembic Pharmaceuticals Inc. | 1 | capsule, extended release | Generic drugs (ANDA) | November 3, 2022 |
| Alembic Pharmaceuticals Limited | 1 | capsule, extended release | Generic drugs (ANDA) | November 3, 2022 |
| Allergan, Inc. | 1 | suppository | New drug applications (NDA) | January 5, 2001 |
| Amneal Pharmaceuticals LLC | 1 | tablet, delayed release | Generic drugs (ANDA) | February 19, 2025 |
| Ani Pharmaceuticals, Inc. | 1 | enema | Authorized generics (NDA) | May 13, 2016 |
| Ani Pharmaceuticals, Inc. | 1 | suspension | Generic drugs (ANDA) | May 14, 2026 |
| Aphena Pharma Solutions - Tennessee, LLC | 1 | tablet | Authorized generics (NDA) | July 1, 2003 |
| Apotex Corp. | 1 | capsule | Generic drugs (ANDA) | December 28, 2007 |
| Ascend Laboratories, LLC | 1 | capsule, extended release | Generic drugs (ANDA) | July 16, 2021 |
| Aurobindo Pharma Limited | 1 | capsule, extended release | Generic drugs (ANDA) | March 31, 2023 |
| AvKARE | 1 | tablet, delayed release | Generic drugs (ANDA) | September 25, 2024 |
| Carnegie Pharmaceuticals LLC | 1 | capsule | Generic drugs (ANDA) | June 30, 2025 |
| Encube Ethicals, Inc. | 1 | suspension | Generic drugs (ANDA) | June 1, 2023 |
| Hikma Pharmaceuticals USA Inc. | 1 | capsule | Generic drugs (ANDA) | December 28, 2007 |
| Ingenus Pharmaceuticals, LLC | 1 | capsule, extended release | Generic drugs (ANDA) | September 23, 2024 |
| KLM Laboratories Private Limited | 1 | suspension | Generic drugs (ANDA) | September 1, 2026 |
| Lannett Company, Inc. | 1 | tablet, delayed release | Generic drugs (ANDA) | June 3, 2023 |
| Major Pharmaceuticals | 1 | tablet, delayed release | Generic drugs (ANDA) | June 19, 2017 |
| Mylan Pharmaceuticals Inc. | 1 | capsule, extended release | Generic drugs (ANDA) | November 26, 2019 |
| Nordic Pharma, Inc. | 1 | suppository | Generic drugs (ANDA) | June 24, 2019 |
| NorthStar Rx LLC | 1 | suppository | Generic drugs (ANDA) | August 25, 2021 |
| NorthStar RxLLC | 1 | tablet, delayed release | Generic drugs (ANDA) | December 1, 2024 |
| Nuvaila Limited | 1 | tablet, delayed release | Generic drugs (ANDA) | July 1, 2026 |
| PD-Rx Pharmaceuticals, Inc. | 1 | capsule | Generic drugs (ANDA) | December 28, 2007 |
| Padagis Israel Pharmaceuticals Ltd | 1 | enema | Generic drugs (ANDA) | October 11, 2007 |
| Remedyrepack Inc. | 1 | tablet | Authorized generics (NDA) | January 28, 2019 |
| Salix Pharmaceuticals, Inc. | 1 | capsule, extended release | New drug applications (NDA) | October 31, 2008 |
| Teva Pharmaceuticals, Inc. | 1 | tablet, delayed release | Generic drugs (ANDA) | August 22, 2024 |
| Upsher-Smith Laboratories, LLC | 1 | capsule, extended release | Generic drugs (ANDA) | June 6, 2023 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, delayed release | 25 | 29.8% |
| Capsule, extended release | 18 | 21.4% |
| Tablet | 11 | 13.1% |
| Capsule | 11 | 13.1% |
| Suppository | 9 | 10.7% |
| Suspension | 5 | 6% |
| Enema | 2 | 2.4% |
| Capsule, delayed release | 2 | 2.4% |
| Capsule, gelatin coated | 1 | 1.2% |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.